Vertex Pharmaceuticals chief Reshma Kewalramani said AI could reduce the time spent on drug-approval paperwork from months to ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.

Vertex Pharmaceuticals should fare better in a down market than most stocks. The big biotech innovator has tremendous growth prospects. The stock offers an attractive risk-reward proposition. 10 ...

After Maze Therapeutics opted not to participate in the National Advertising Division’s (NAD’s) self-regulatory process for monitoring promotional claims, a case brought by competitor Vertex ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising new drugs on the horizon. Vertex's price looks quite attractive, relative to ...

One of Vertex's pipeline disappointments was that VX-993 didn't meet the primary endpoint in a phase 2 study evaluating the NaV1.8 pain signal inhibitor in treating acute pain following bunionectomy ...